Here’s what we have for you today:
• Gene mutation
• Running AI
• Branch production
Nvidia buying another tech company
Running out: Reportedly Nvidia is acquiring Run:ai for $700 million to $1 billion.
Use case: Run:ai helps operational teams to manage their AI infrastructure.
Back then: Run:ai’s CEO Omri Geller stated “Run:ai has been a close collaborator with Nvidia since 2020 and we share a passion for helping our customers make the most of their infrastructure.”
Walgreens launching service for U.S. patients
Pharmaceutical therapies: Walgreens announced on late April 2024 that it will start to work directly with drugmakers to bring cell and gene therapies to patients in the United States.
For reference: The U.S. Food and Drug Administration approved 7 cell and gene therapies in 2023.
The review: The FDA believes it will be reviewing and approving between 10 to 20 cell and gene therapies annually by 2025.
Oil from Spain’s olive branch
Weather or not: Climate change have impacted olive oil production in southern Europe in recent years.
Slippery Trees: Reportedly from the Centre for Promotion of Imports, Spain supplies 40%+ of the world’s olive oil production.
More oil: Spain cultivated around 666,000 metric tons for 2022-2023, for 2023-2024 the expectation is a production range of 830,000 to 850,000 metric tons.